ELSA CORREA-DELEONARDO: Open Payments
NPI 1396222907 · REISTERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,612 in 103 payments from 12 companies in 2025. Trend: 2023 $1,777 · 2024 $2,390 · 2025 $2,612
Food & beverage: $2,612
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $387 |
| Teva Pharmaceuticals USA, Inc. | 12 | $385 |
| Alkermes, Inc. | 22 | $364 |
| E.R. Squibb & Sons, L.L.C. | 8 | $331 |
| Axsome Therapeutics, Inc. | 8 | $275 |
| Neurocrine BioSciences, Inc. | 3 | $244 |
| Otsuka America Pharmaceutical, Inc. | 14 | $172 |
| ABBVIE INC. | 14 | $157 |
| Lundbeck LLC | 5 | $112 |
| Vanda Pharmaceuticals Inc. | 3 | $91 |
Products named: CAPLYTA, ARISTADA, UZEDY, COBENFY, Auvelity, INGREZZA, REXULTI, VRAYLAR.
Industry payments across MD — which companies pay providers there.
